Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.
As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.
In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.